RPL17 and neoplasm: Here we report the discovery of a novel LAG3 antibody, which showed a strong potency in the T cell activation and tumor growth inhibition in combination with anti-PD-L1 antibodies, indicating a potential therapeutic value of this antibody as a combination partner with PD-1 or PD-L1 agent.